Lillo Lauricella

Molecolular Pathologist at Niguarda Cancer Center

[Hidehito HORINOUCHI @HHorinouchi]

🔥ASCO Living Guideline update: Stage IV NSCLC without driver alterations 2026.3.1
🆙 @JCO_ASCO
☑Latest update incorporating new evidence for ICI-based regimens in stage IV NSCLC
🎙Dr. Lyudmila Bazhenova @HHorinouchi
#LCSM @OncoAlert @Larvol
https://t.co/k4lOuFfjrl

[Mihaela Aldea @mihaela_aldea]

@IASLC recommendations on Molecular Tumor Boards out in @JTOonline
#PrecisionMedicine #MTB
https://t.co/KZQgHpTWfb

[soria @jsoriamd]

🧬 MSI-H = hallmark of mismatch repair (MMR) deficiency.
🧵 Prevalence: ~30% endometrial, ~10% CRC, ~8% gastric.
But not all MSI-H/dMMR tumors are alike:
1️⃣ MSH2/MSH6 loss → ↑ TMB, better ICI response
2️⃣ PTEN/AKT1 mutations → ICI resistance
Checkpoint blockade is now 1L in CRC & endometrial.
#MSI #Immunotherapy #Biomarkers
🔗 https://t.co/E7eGcMtJUy

[International Society of Liquid Biopsy @isliquidbiopsy]

🚨 cfRNA is Here — and It’s a Game Changer! 🧬🩸
@max_diehn et al., @Nature 2025

🔗 DOI: 10.1038/s41586-025-08834-1

👏 From one of our #ISLB awardees!

🔍 Key Highlights:

✅ RAREseq: A new method for ultrasensitive cfRNA profiling 💡

✅ cfRNA detects early-stage NSCLC with higher sensitivity than ctDNA 📈

✅ Reveals genetic & non-genetic resistance to EGFR TKIs in plasma 🧪

✅ Captures tumor-specific expression patterns beyond mutation status 🔬

✅ Enables real-time disease monitoring in patients on targeted therapy ⏱️

💡 cfRNA is poised to complement and even surpass ctDNA in key clinical settings.

@ChristianRolfo @ElJanLe @DrYukselUrun
@UmbertoMalapel1 @drgandara @MJOSESERRANO19

#LiquidBiopsy #cfRNA #NSCLC #EGFR #CancerDiagnostics #PrecisionOncology #ISLB 🚀

[Patologia Molecolare e Medicina di Precisione @pmmpitalia]

237 volte grazie: grazie agli anatomopatologi, ai biologi, ai biotecnologi, agli oncologi, agli infermieri, ai genetisti, ai tecnici di laboratori biomedici. Grazie a tutte e tutti voi! Ci vediamo l'anno prossimo a Napoli 🌋
#PMMP25 ➡️ #PMMP26 @UmbertoMalapel1 @FabioPagni1

[Lillo Lauricella @LilloCalos]

https://t.co/PGzm160gdm

[JTO & JTO CRR @JTOonline]

This manuscript from the IASLC Pathology Committee proposes a combined histologic and molecular algorithm in categorizing multiple lung adenocarcinomas into SPLCs or IPMs, specifically that genomic profiling by NGS should be performed whenever possible. https://t.co/P9FHlTcqpB

[Patologia Molecolare e Medicina di Precisione @pmmpitalia]

🚀 È online il sito del gruppo PMMP della SIAPEC!
Punto di riferimento per la Patologia Molecolare e la Medicina di Precisione 🧬🔬
Scopri le nostre iniziative, raccomandazioni e collaborazioni!

🔗 Visita il sito: https://t.co/akelQkACOO
#PMMP #SIAPEC

[SIAPeC-IAP @SIAPeC_IAP]

🎯 XI Incontro Nazionale @pmmpitalia
📷11-12 aprile 2025
📍Firenze
🔗https://t.co/I6zzcItctp
#PrecisionMedicine #SIAPeC

@UmbertoMalapel1 @FabioPagni1

[Lillo Lauricella @LilloCalos]

@eliogreg @ESMO_Open @AgostaraAlberto @MOcchipintiMD @MartaBrumby @CarloGenova5 @rossana_berardi @mirkomontrone @Ste_ita @ClaudiaProto83 A Big Team Work

[Lillo Lauricella @LilloCalos]

https://t.co/AVvMLeVnV5

[Lillo Lauricella @LilloCalos]

@MariantoniaNac1 @DavideSeminati @CalogeroLauric7 @UmbertoMalapel1 @siapec @gianlucar93 @FabioPagni1 @KonVenetis @MSalatiello @NicolaFuscoMD @PasqualePisapia Thanks

[Lillo Lauricella @LilloCalos]

@MariantoniaNac1 @UmbertoMalapel1 @4oncommunity @FabioPagni1 @gianlucar93 @isliquidbiopsy @KonVenetis @MSalatiello @NicolaFuscoMD @PasqualePisapia Thanks

[Stephen V Liu, MD @StephenVLiu]

Press release: phase III LAURA trial meets primary endpoint. Stage III #EGFR NSCLC post chemoradiation, indefinite osimertinib superior to placebo. No surprise - eager to see magnitude of benefit, patterns of relapse, OS trends, and crossover rate…

https://t.co/5BKEDnlSoH

[Fondazione Oncologia Niguarda Onlus @nig_onco]

Il programma di cure oncologiche a Niguarda Cancer Center riguarda anche i tumori rari, tra cui il sarcoma cardiaco: un raro tumore maligno che il team dell'@ospniguarda si occupa di trattare e studiare, grazie alla Fondazione.

Scopri di più https://t.co/Egj5DEghSw

[Lillo Lauricella @LilloCalos]

Proud to share our case report#Acute promyelocytic leukemia with del(6)(p22) and atypical bcr2 PML::RARA fusion transcript: a case report. https://t.co/lHyPnovhxd

[Lillo Lauricella @LilloCalos]

#WeareSpalla

[Lillo Lauricella @LilloCalos]

https://t.co/eFs3YkaUYf

[Annals of Oncology @Annals_Oncology]

The use of NGS on DNA🧬 from tissue or liquid biopsies is now well established in the management of patients with cancer. In this Letter to the Editor, @ArBayle and coll. present the data from cases tested with both modalities in PRISM 🇫🇷
https://t.co/nzTbEDFfCE

[[email protected] @FabioPagni1]

https://t.co/ESt9ggWUlf

[Elio Gregory Pizzutilo @eliogreg]

Activity of #osimertinib in #nsclc with uncommon #EGFR mutations.
It’s a pleasure to share the first data of multicenter #Articuno study at #WCLC22 #LCSM